NCT07916961Not yet recruitingPhase 1
Study of AB-110 in Healthy and Hypertensive Participants
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-110 in Healthy and Hypertensive Participants
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
This Phase 1, randomized, double-blind study is designed to evaluate safety, tolerability, PK, and PD effects of AB-110. This study will be conducted in 2 parts: a single ascending dose (SAD; Part A) in healthy participants with an optional cohort of BMI \> 30 kg/m2 and ≤ 35 kg/m2 and multiple ascending dose (MAD; Part B) in participants with hypertension who are otherwise healthy. Sentinel dosing will be applied in the Part A study at each new dose level to ensure participant's safety. The study will provide initial insight into the safety and tolerability of AB-110. In addition to safety, the study is designed to enable insights on secondary and exploratory research questions, including Blood Pressure (BP) reduction and exploratory biomarkers.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 104 (estimated)
- First submitted
- 22 Oct 2026
- Start date
- Nov 2026
- Primary completion date
- Sept 2027
- Lead sponsor
- Antlia Bioscience, Inc
- Diseases
- High blood pressure
- NCT number
- NCT07916961
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 104
- From Nov 2026 to the primary completion date, Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Has recently received an investigational agent
Other illness
- Has secondary hypertension
- Has history of any cardiovascular event
Lab values
- Has estimated glomerular filtration rate (eGFR) of \<60 mL/min/1.73m\^2
Other
- Has orthostatic hypotension
- Other inclusion/exclusion criteria may apply
Who the study is looking for
- Part A 18 - 50 years of age; Part B 18 -65 years of age.
- Part A SBP ≥130 and below 140mmHg and healthy; Part B \>140 and ≤165 mmHg
- Part A Body Mass Index in the range of 18 - 30 kg/m2, and minimal weight of 50 kg; Part B 18 - 32 kg/m2, and minimal weight of 50 kg
- Has a normal 12-lead electrocardiogram (ECG)
- Is a nonsmoker
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Auckland | New Zealand | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.